Amgen Paying $1.3 Bil. For Tularik; Deal Brings Two Late-Stage Oncologics
Amgen is acquiring two late-stage oncology compounds through its $1.3 bil. buyout of Tularik
You may also be interested in...
Having raised a precedent-setting $450m venture capital round in January 2015, Moderna is well on its way to a planned $600m additional fundraising. The privately held company is keeping quiet about what it's doing with all that cash. Tioma, Nutrina and Avelas are among other firms receiving VC financing.
Dependent on revenues from AstraZeneca-partnered fostamatinib to fund its growth, Rigel has built a diverse and innovative portfolio. But disappointing results from a Phase IIb dose-ranging trial of fostamatinib – three other pivotal trials will report out soon – could signal trouble for the biopharma. Rigel execs Jim Gower and Raul Rodriguez share perspectives on the AstraZeneca deal and fostamatinib’s prospects.
Amgen's 2004 R&D targets include a BLA filing for palifermin for reduction of oral mucositis associated with radiation and chemotherapy in patients with hematologic malignancies